Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Aeluma Q2 FY2026 Earnings Call - Early Commercial Momentum with Initial Sales Orders, Quantum Wins, and $38.6M Cash
Aeluma says the transition to commercialization is under way. Management reported modest but meaningful initial sales orders and rising RFQs across mobile, data center AI, defense, and quantum, while ...
- Aeluma reports increasing customer engagement, shifting from interest to pricing and planning, and has begun taking initial sales orders, though orders are small and customers unnamed.
- Q2 revenue was $1.3 million, down from $1.6 million a year ago and roughly flat versus Q1, driven primarily by government R&D contracts tied to milestone timing.
- GAAP net loss for the quarter was $1.9 million, or $0.11 per share; adjusted EBITDA loss was $917,000.
- +11 more takeaways
HubSpot Q4 2025 Earnings Call - AI Agents and Upmarket Momentum Turn Platform into Growth Engine
HubSpot closed 2025 with high-teens growth, improving margins, and a clear pivot: convert unified customer context into agentic AI work that drives measurable outcomes. Q4 revenue rose about 18% in co...
- Q4 2025 revenue grew 18.2% year-over-year in constant currency; full-year 2025 revenue was $3.1 billion.
- HubSpot delivered strong operating leverage: Q4 operating margin around 22.6% (non-GAAP cited at ~23%), full-year operating margin 18.6% and free cash flow of $595 million for 2025.
- Customer base exceeded 288,000, with 9,800 net new customers added in Q4 and more than 40,000 net adds for the year.
- +13 more takeaways
McDonald’s Q4 2025 Earnings Call - Accelerating store growth and a 'three for three' play (value, marketing, menu) is driving comp momentum
McDonald’s closed 2025 with tangible momentum: system-wide sales approached $140 billion, global comparable sales accelerated in Q4, and loyalty engagement is scaling fast. Management pinned the win t...
- System-wide sales approached $140 billion in 2025, up 5.5% in constant currency for the year; global comparable sales were up 5.7% in Q4 with positive guest counts.
- U.S. Q4 comps rose 6.8%, above expectations, driven by a mix of positive check and guest count growth tied to value, marketing, and menu initiatives.
- McDonald’s opened 2,275 restaurants in 2025 (gross) with net additions of 1,880; management is targeting ~2,600 gross openings in 2026 and remains on track for 50,000 restaurants by end-2027.
- +12 more takeaways
Ascendis Pharma Q4 2025 Earnings Call - Strong commercial scale-up and a bold EUR 500m 2026 operating cash flow target with TransCon CNP approval imminent
Ascendis closed 2025 with clear commercial momentum, two growing TransCon products and an ambitious financial roadmap. Europat (hypoparathyroidism) and SKYTROFA (once-weekly growth hormone) drove FY r...
- Q4 Europat revenue was EUR 187 million, bringing full-year 2025 Europat revenue to EUR 477 million.
- SKYTROFA (TransCon Growth Hormone) posted Q4 revenue of EUR 53 million and FY 2025 revenue of EUR 206 million; US market share around 7%.
- Total Q4 revenue was EUR 248 million, and total revenue for FY 2025 was EUR 720 million.
- +15 more takeaways
Neurocrine Biosciences 4Q 2025 Earnings Call - CRENESSITY Launch and INGREZZA Momentum Set Stage for 2026 Growth
Neurocrine closed 2025 with clear commercial momentum, driven by INGREZZA durability and a surprisingly strong first full year for CRENESSITY. Total product sales topped $2.8 billion, up 22% year over...
- Total product sales exceeded $2.8 billion in 2025, up 22% year over year, driven by INGREZZA and the first full-year of CRENESSITY sales.
- INGREZZA delivered just over $2.5 billion in revenue for 2025, up 9% year over year, with management forecasting approximately $2.7 to $2.8 billion in 2026, about 10% growth.
- Management expects INGREZZA 2026 growth to be volume driven, with double-digit unit growth offset partially by price concessions tied to formulary access investments.
- +12 more takeaways
Tamboran Resources FY2026 Q2 Earnings Call - On Track for First Gas in Q3 2026 as SPCF Nears Completion
Tamboran says the pilot is moving from trial to delivery. Management highlights the completion of the largest stimulation program in the Beetaloo so far, the Sturt Plateau compression facility trackin...
- Todd Abbott appointed CEO in January 2026 following an external process, signalling a management reset heading into production.
- Tamboran completed the largest stimulation program to date in the Beetaloo on SS-6H: 58 stages across a 10,009 foot horizontal in the Mid-Velkerri B Shale, executed with H&P FlexRig 3 and Liberty Energy frac fleet.
- Initial flow back from SS-6H identified an impediment at approximately 8,600 feet, potentially blocking flow from the last ~14 percent of the lateral; the impact is under evaluation.
- +15 more takeaways
Viking Therapeutics Q4 and Full Year 2025 Earnings Call - VK2735 advances to Phase 3 in both injectable and oral forms, maintenance study readout due Q3 2026
Viking closed 2025 with a clear, aggressive playbook: push VK2735 across two formulations into registrational studies while financing the effort with roughly $706 million in cash. The company has alre...
- VK2735 is now a dual-path Phase 3 program: subcutaneous VANQUISH program (VANQUISH-1 and VANQUISH-2) is underway and the oral formulation is planned to enter Phase 3 in Q3 2026 after a positive end-of-Phase 2 interaction with the FDA.
- VANQUISH-1 enrollment completed ahead of schedule and exceeded the planned ~4,500 patient target within five months; VANQUISH-2 (target ~1,100 patients, obesity plus type 2 diabetes) is nearing completion.
- VANQUISH trial design: randomized, double-blind, placebo-controlled, once-weekly subcutaneous dosing for 78 weeks with dose arms of 7.5 mg, 12.5 mg, and 17.5 mg, primary endpoint percent change in body weight at 78 weeks, plus extension periods for continued access.
- +12 more takeaways
Cisco Q2 FY2026 Earnings Call - AI Infrastructure Demand Drives Record Revenue, Memory Price Headwind
Cisco posted a clean, unmistakable beat in Q2, delivering record revenue of $15.3 billion, double-digit top- and bottom-line growth, and a clear AI narrative driving the outperformance. Product revenu...
- Record Q2 revenue $15.3 billion, up 10% year-over-year, Non-GAAP EPS $1.04, up 11%
- Total product revenue $11.6 billion, up 14%; services revenue $3.7 billion, down 1%
- Product orders rose 18% year-over-year, and excluding hyperscalers orders were up 10%
- +14 more takeaways
Vanda Pharmaceuticals Q4 2025 Earnings Call - Regulatory wins and product momentum, offset by a one-time $114m tax valuation that blew out 2025 results
Vanda closed 2025 with clear commercial traction and a flurry of regulatory milestones, but the headline numbers are distorted by a large, non-cash tax valuation allowance that turned a modest 2024 lo...
- Total 2025 revenue $216.1 million, up 9% year over year, driven primarily by Fanapt growth.
- Fanapt full-year net product sales $117.3 million, up 24% versus 2024; 2025 TRX rose 28% and new-to-brand prescriptions increased 149% year over year.
- Q4 2025 Fanapt sales $33.2 million, up 25% year over year; Q4 TRX +36% and Q4 NBRX +108% versus prior year quarter.
- +15 more takeaways
Fastly Q4 2025 Earnings Call - Revenue Acceleration and Record Gross Margins Show Profitability Turnaround
Fastly closed 2025 with a clear inflection, reporting a record Q4 and its first profitable fiscal year. Revenue accelerated to $172.6 million in Q4, up 23% year over year, driving a record gross margi...
- Q4 revenue $172.6 million, +23% year-over-year, above the high end of guidance and the largest sequential dollar growth in company history.
- Full-year 2025 revenue $624 million, +15% year-over-year, beating the prior year guidance midpoint.
- Q4 gross margin hit a record 64%, up 650 basis points YoY, driven by volume flow-through and a stronger traffic mix.
- +17 more takeaways